Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2003
06/04/2003EP1315480A2 "slow release" pharmaceutical compositions comprising lithium carbonate
06/04/2003EP1207857B1 Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
06/04/2003EP1165565B1 Optically pure camptothecin analogues
06/04/2003EP1105390B1 Imidazo[1,2-a]pyridine derivatives for the treatment of gastrointestinal diseases
06/04/2003EP1095007B1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use
06/04/2003EP1051413B1 Quinoline derivatives as antibacterials
06/04/2003EP1049666B1 Novel naphthyl-substituted and anilide-substituted sulfonamides
06/04/2003EP1007031B1 4-cyano-4-deformylsordarin derivatives
06/04/2003EP0969821B1 Pellets having a core coated with an antifungal and a polymer
06/04/2003EP0944616B1 Bicyclic aryl carboxamides and their therapeutic use
06/04/2003EP0904098B1 Compositions comprising antifungal agent and acetate buffer
06/04/2003EP0885010B1 Intercellular adhesion molecule powder formulation
06/04/2003EP0814839B1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
06/04/2003EP0783507B1 Compounds useful as antiproliferative agents and garft inhibitors
06/04/2003EP0775118B1 Benzimidazole derivatives having dopaminergic activity
06/04/2003EP0759437B1 Processes for the production of 2-isocephem derivatives
06/04/2003EP0692028B1 Pharmaceuticals based on papillomaviruses
06/04/2003EP0672116B1 Deletion mutants as vaccines for cholera
06/04/2003EP0665752B1 Pharmaceutical compositions containing 3-beta-hydroxylated natural steroid derivatives, and use thereof
06/04/2003EP0656037B1 Metal-mediated cross-coupling with ring-metalated porphyrins
06/04/2003CN1422283A Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
06/04/2003CN1422279A Selective N-acylation of A82846 glycopeptide analogs
06/04/2003CN1422277A Novel substance having physiological activity, process for producing the same, and use
06/04/2003CN1422273A 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases
06/04/2003CN1422269A 1H-imidazopyridine derivatives
06/04/2003CN1422262A 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
06/04/2003CN1422259A Crystalline pharmaceutical
06/04/2003CN1422256A Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredent
06/04/2003CN1422253A Carbamate caspase inhibitors and uses thereof
06/04/2003CN1422252A Chemokine receptor antagonists
06/04/2003CN1422162A Composition and method for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
06/04/2003CN1422158A Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
06/04/2003CN1422156A Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
06/04/2003CN1422155A Urease inhibitors
06/04/2003CN1422142A Pharmaceutical composition
06/04/2003CN1421531A Prepn process of humanized monoclonal antibody resisting hepatitis B virus surface antigen
06/04/2003CN1421452A Structure and prepn of 2,6-branched oligosaccharide with medicinal application foreground
06/04/2003CN1421451A 9-[2-[[[di (trimethylacetoxyl) methyl phosphoroso] methoxy]-ethyl] adenine crystal and its prepn and crystal application
06/04/2003CN1421450A Prepn of 9 [2-[[[di (trimethylacetoxyl) methyl] phosphoros]-methoxy-ethyl] adenine
06/04/2003CN1421449A 9-[2-[[[di (trimethylacetoxyl) methyl] phosphoroso] methoxy]-ethyl] adenine crystal and its prepn and crystal application
06/04/2003CN1421238A Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity
06/04/2003CN1421234A Oral liquid for treating hepatitis B
06/04/2003CN1421231A Chinese medicine fast-acting ointment for treating septicemia
06/04/2003CN1421229A Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer
06/04/2003CN1421206A Medical composition
06/04/2003CN1421202A Antiviral and antibacterial cantharidinic anhydride medicine composition and its prepn process
06/04/2003CN1421192A Recipe and prepn process of skin care article
06/04/2003CN1421191A Medicine powder for eliminating foot smell and bromhidrosis and its prepn process
06/04/2003CN1110492C Prodrugs of aspartyl protease inhibitors
06/04/2003CN1110491C Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
06/04/2003CN1110484C 2-(cary lphenyl) amino-imidazoline derivatives
06/04/2003CN1110323C Rotavirus resisting immune globulin composition and its producing process and use
06/04/2003CN1110307C Medicine for curing tinea unguium
06/04/2003CN1110303C Application of eight precious extract in preparing antiviral medicine
06/04/2003CN1110299C Triazazole nucleoside aerosol and its preparing method
06/03/2003US6573378 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt
06/03/2003US6573367 Derivatives from the class of oleandomycin
06/03/2003US6573273 Urea substituted imidazoquinolines
06/03/2003US6573272 Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: which inhibit FabI and are useful for the treatment of bacterial infections.
06/03/2003US6573265 Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents;
06/03/2003US6573260 Cycloalkyl-substituted aminomethylpyrrolidine derivatives
06/03/2003US6573259 Inhibitors of interleukin-1β converting enzyme
06/03/2003US6573258 Photodynamic porphyrin antimicrobial agents
06/03/2003US6573248 Monocyclic L-nucleosides, analogs and uses thereof
06/03/2003US6573247 Prophylaxis or treatment of varicella-zoster virus or cytomegalo virus infections
06/03/2003US6573246 Modified ether glyceroglycolipids
06/03/2003US6573245 Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
06/03/2003US6573244 Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
06/03/2003US6573095 Polynucleotides isolated from skin cells
06/03/2003US6573082 Streptococcus pneumoniae antigens and vaccines
06/03/2003US6573081 Method for growing circoviruses
06/03/2003US6573079 Methods and interferon deficient substrates for the propagation of viruses
06/03/2003US6573078 Human immunodeficiency virus (HIV) protein fragments having antiviral activity; peptides derived from HIV transmembrane glycoprotein that inhibit HIV-induced cell-cell fusion; use for inhibition of enveloped viral infection
06/03/2003US6573066 FtsH from Staphylococcus aureus
06/03/2003US6573003 Soluble recombinant fusion protein comprising a nontoxin protein sequence and portion of Clostridium difficile toxin B amino acid sequence 10; pseudomembranous enterocolitis; side effect free; low cost
06/03/2003US6572875 Biodegradable microbicidal vaginal barrier device
06/03/2003US6572863 Genome is modified to disable VPR and TAT to prevent their expression; stop codons to prevent translation
06/03/2003US6572861 Lecithin, oil in water emulsion and an amphiphilic surfactant; minimize local reactions to the vaccine
06/03/2003US6572860 ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E or glycoprotein F and an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class of T cells and
06/03/2003US6572856 Classic complement pathway, C3 convertase
06/03/2003US6572853 Recombinant human beta interferon with enhanced solubility
06/03/2003CA2101639C Herpes simplex virus-1 deletion variants and vaccines thereof
05/2003
05/30/2003WO2003044524A2 Methods and means for influencing intracellular communication and intracellular organelle transport
05/30/2003WO2003044184A1 Treatment of pml targeting jc virus agno
05/30/2003WO2003044183A1 Interleukin-2 gene transferred lymphokine activated killer cells
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044053A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003WO2003044049A1 Antimicrobial polypeptides from pseudoplectania nigrella
05/30/2003WO2003044048A2 Methylated heparin-binding hemagglutinin (hbha) recombinant mycobacterial antigen
05/30/2003WO2003044047A2 Virulence proteins of the genus yersinia and uses thereof
05/30/2003WO2003044031A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044009A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043999A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043982A1 Derivatives of andrimide and moiramide b having antibacterial properties
05/30/2003WO2003043979A2 Pharmaceutically active compounds and methods of use thereof
05/30/2003WO2003043966A2 Clusianon isomers and use thereof
1 ... 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 ... 1798